Table 1 Baseline demographic, clinical and anthropometric characteristics of the study patients.

From: Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)

Variables

NEPA + DEX1 (n = 76)

NEPA + DEX4 (n = 76)

P-value*

Age (years), mean (SD)

64.4 (7.2)

63.6 (7.9)

0.45

Female sex, n (%)

21 (27.6)

22 (28.9)

1.00

Weight (Kg), mean (SD)

70.2 (13.5)

72.5 (12.7)

0.27

BMI (kg/m2), mean (SD)

24.7 (4.1)

25.4 (3.9)

0.28

Healthy weight (18.5–24.9 kg/m2), n (%)

43 (56.6)

37 (48.7)

0.69

Overweight (25–29.9 kg/m2), n (%)

26 (34.2)

30 (39.5)

 

Obese (≥ 30 kg/m2), n (%)

7 (9.2)

9 (11.8)

 

ECOG PS, n (%)

  

0.22

 0

63 (82.9)

58 (76.3)

 

 1

13 (17.1)

18 (23.7)

 

Tumor stage, n (%)

  

0.34

 Early

20 (26.3)

16 (21.1)

 

 Locally advanced

27 (35.5)

22 (28.9)

 

 Metastatic

29 (38.2)

38 (50)

 

Alcohol intake, n (%)

  

0.48

 Never

55 (72.4)

50 (65.8)**

 

 Everyday

21 (27.6)

26 (34.2)

 

Percentage WL in previous 6 months

   

 Mean (SD)

− 1.6 (5.5)

− 2.3 (5.1)

0.39

***Pre-chemotherapy food intake, n (%)

  

0.50

More than usual

7 (9.2)

11 (14.4)

 

Unchanged

48 (63.2)

42 (55.3)

 

Less than usual

21 (27.6)

23 (30.3)

 

BMI-adjusted WL grade, n (%)

  

0.17

 0

29 (38.2)

28 (36.8)

 

 1

23 (30.3)

19 (25)

 

 2

4 (5.2)

14 (18.4)

 

 3

15 (19.7)

10 (13.2)

 

 4

5 (6.6)

5 (6.6)

 
  1. NEPA fixed combination of netupitant and palonosetron, DEX1 dexamethasone day 1, DEX4 dexamethasone day 1 to 4, SD standard deviation, BMI body mass index, ECOG PS Eastern Cooperative Oncology Group performance status, WL weight loss.
  2. *p-value was calculated using Fisher’s exact test, chi-square test, and Mann–Whitney U-test as appropriate; all tests were two-tailed.
  3. **Including a patient with missing data.
  4. ***As compared with their normal food intake, patients self-rated food intake during the past month before the study entry.